Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase II clinical trials for the treatment of solid tumors, including renal, head and neck, ovarian and trip...
Industry: Biotechnology
Sector: Healthcare
Phone: 44 18 6558 2066
Address:
Bellhouse Building, Unit 202 Oxford Science Park Sanders Road, Oxford, United Kingdom
